Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Assessment of the influence of telmisartan, lacidipine and their combination on the QTC interval of the ECG
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Telmisartan high | Experimental |
| |
| Telmisartan low | Experimental |
| |
| Lacidipine high | Active Comparator |
| |
| Lacidipine low | Active Comparator |
| |
| Telmisartan+Lacidipine | Experimental |
| |
| Placebo | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Telmisartan high | Drug |
| ||
| Telmisartan low |
| Measure | Description | Time Frame |
|---|---|---|
| Average QTcF (QT interval Fridericia correction) change | baseline, day 1, day 7 |
| Measure | Description | Time Frame |
|---|---|---|
| Change in QT interval | baseline, day 1, day 7 | |
| Change in QTcB (QT interval Bazett correction) interval | baseline, day 1, day 7 | |
| Change in PQ interval |
Not provided
Inclusion Criteria:
All participants in the study should be healthy males/females, range from 21 to 50 years of age and their body mass index (BMI) be within 18.5 to 29.9 kg/m2.
In accordance with Good Clinical Practice and local legislation all volunteers will have given their written informed consent prior to admission to the study.
Exclusion Criteria:
Following exclusion criteria are of special interest for this study:
For female subjects:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Lacidipine high | Drug |
|
| Lacidipine low | Drug |
|
| Placebo | Drug |
|
| baseline, day 1, day 7 |
| Change in QRS interval | baseline, day 1, day 7 |
| Change in RR interval | baseline, day 1, day 7 |
| Change in heart rate (HR) | baseline, day 1, day 7 |
| Occurrence of ECG abnormalities | baseline, day 1, day 7 |
| Change in T wave morphology | normal, flat, inverted, biphasic | baseline, day 1, day 7 |
| Change in U wave morphology | normal, abnormal | baseline, day 1, day 7 |
| Area under the plasma concentration time curve (AUC) | day 1, day 7 |
| Maximum plasma concentration (Cmax) | day 1, day 7 |
| Time to attain maximum plasma concentration (tmax) | day 1, day 7 |
| Trough plasma concentration at steady state (Cmin,ss) | day 7 |
| Number of participants with adverse events | up to 8 days after last treatment |